Lucid Diagnostics Dividends
| LUCD Stock | USD 0.81 0.02 2.11% |
The current year's Dividend Paid And Capex Coverage Ratio is expected to grow to -141.07. Lucid Diagnostics' past performance could be the main factor of why investors trade Lucid Diagnostics stock today. Investors should clearly understand every aspect of the Lucid Diagnostics dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Lucid Diagnostics' dividend schedule and payout information. Lucid Diagnostics dividends can also provide a clue to the current valuation of Lucid Diagnostics.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (148.49) | (141.07) |
Lucid Diagnostics Quarterly Total Cash From Financing Activities |
|
Lucid |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Lucid Diagnostics must own a stock before its ex-dividend date to receive its next dividend.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.